IE
LBRX

Israel Englander’s LB Pharmaceuticals LBRX Stock Holding History

Israel Englander’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.41M Buy
259,219
+122,253
+89% +$3.59M ﹤0.01% 2467
2026
Q1 		$3.38M Buy
+136,966
New +$3.16M ﹤0.01% 3360
2025
Q4 		– Sell
-538,169
Closed -$8.5M – 6641
2025
Q3 		$8.5M Buy
+538,169
New +$8.54M ﹤0.01% 2559

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Israel Englander's LBRX Position: Q2 2026 in Review

Israel Englander increased its LB Pharmaceuticals (LBRX) stake by 89% in Q2 2026, buying an estimated $3.59M and bringing the position to 259,219 shares worth $8.41M. The position accounts for ﹤0.01% of the portfolio, ranked #2467.

Israel Englander first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $8.5M in Q3 2025. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Israel Englander held 259,219 shares of LB Pharmaceuticals worth $8.41M as of Q2 2026.
  • Israel Englander bought 122,253 LB Pharmaceuticals shares in Q2 2026, an estimated $3.59M.
  • LB Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2467 holding.
  • Israel Englander first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Israel Englander's LB Pharmaceuticals position peaked at $8.5M in Q3 2025.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.